Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.

ESMO Open · 2016 · PMC5070302 · PMID 27843622

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendp=0.053so close (0.05 < p ≤ 0.1)

Letrozole 0.5 mg showed a trend (p=0.053) towards a survival benefit. 21 The second study included 551 patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.